HEMOPHILIA TREATMENT MARKET ANALYSIS

Global Hemophilia Treatment Market- Regional Analysis

Among region, North America is expected to dominate the global hemophilia treatment market over the forecast period, due to North Americas’ 39.1% market share and  increasing product approvals from regulatory authorities in the region. For instance, in December 2022, Genentech, an U.S. based biotechnology corporation, announced interim results from phase III HAVEN 7 study. This  study showed  Hemlibra (emicizumab-kxwh), a prescription medicine used for routine prophylaxis had achieved meaningful bleed control with a favorable safety profile in infants (up to 12 months) with severe hemophilia A without factor VIII inhibitors.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa